1 Minute Signal

David Friedberg: Scientists just REVERSED skin age from 70 years to 31

Video thumbnail: David Friedberg: Scientists just REVERSED skin age from 70 years to 31
Jul 18, 20261m 43s video lengthAll-In Podcast

The Signal

Researchers have engineered a novel enzyme using AlphaFold and directed evolution designed to degrade CML, a molecule linked to aging within the extracellular matrix. While biochemical tests show significant CML reduction in both isolated proteins and elderly human skin samples, massive claims regarding age reversal and multi-trillion-dollar market potential remain purely speculative.

The Case

Experimental Results

  • Scientists designed a non-natural protein that demonstrated remarkable effectiveness against a specific target, reportedly eliminating 52% to 97% of CML from substrates including collagen, casein, and hemoglobin.0:34
  • In tests on donated skin from patients over 70 years old, the enzyme reportedly reduced CML levels by 55%, a result the project proponents interpret as effectively "reversing" the tissue age to that of a 31-year-old.

Methodology and Claims

  • The development relied on a combined computational and laboratory approach, utilizing AlphaFold—a protein structure prediction tool—alongside directed evolution and high-throughput screening to create the enzyme.1:10
  • Discussion of the work prematurely jumps to a theoretical consumer application: a topical skin cream; however, no evidence exists regarding whether the large protein could achieve systemic absorption or stability in such a delivery format.
  • The narrative surrounding the technology includes aggressive commercial projections of a "trillion-dollar" or "$2 trillion" market, which are presented without supporting analysis or clinical validation.1:30

The 1 Minute Signal Take

While the biochemical degradation of CML in laboratory samples is a verifiable technical achievement, the leap to "age reversal" and massive commercial valuations is not supported by the provided data. Skeptics should distinguish between the successful protein engineering demonstrated in the study and the speculative marketing claims currently attached to it.

Pro Analysis

Why it Matters

This report represents a common intersection point between state-of-the-art synthetic biology and the highly lucrative anti-aging industry. If a protein can be engineered to specifically catalyze the destruction of accumulated metabolic 'trash' like CML, it changes the paradigm from masking aging to reversing it at the molecular architecture level.

Strategic Implications

The ability to design bespoke enzymes for specific toxic protein targets creates a massive pipeline for drug discovery beyond skin care. If the platform holds up, the same methodology could theoretically be used to address other age-associated protein accumulations in the eyes or circulatory system.

Evidence & Hype Audit

This content is high-hype and low-evidence regarding clinical outcomes. The biochemical efficacy data is presented as a firm finding, but the narrative leaps—specifically the '31-year-old' equivalence and the '$2 trillion' market valuation—are classic promotional extrapolations. There is no mention of control groups, degradation durability, or the biological consequences of removing CML in a living system.

Counterarguments

Critics would point out that biomarkers like CML are often correlations rather than sole causes of aging. Simply removing a byproduct may not reverse the aging process if the underlying cellular signaling pathways have already undergone irreversible epigenetic or structural damage.

Who Should Care

  • Biotech Investors: Focus on the underlying platform's scalability rather than the skin-cream application.
  • Dermatologists: Watch for future studies on skin barrier penetration and potential immunogenic reactions to synthetic enzymes.
  • Cosmeceutical Industry: Monitor if this enzyme can maintain structural integrity in topicals.

What to do next

  • Look for peer-reviewed studies documenting the enzyme’s long-term effect on living tissue.
  • Check for safety data regarding enzyme-induced skin irritation or off-target protein degradation.
  • Investigate whether the CML reduction is transient or if the 'aged' matrix reforms rapidly.
  • Seek independent confirmation of the methodology used for the '31-year-old' skin age assessment.

Share this

Tags

AlphaFold

Written by: 1 Minute Signal Editorial Team